IP Review

This fragment is available on copyright.html

This publication includes IP covered under the following statements.

Copyright HL7. Licensed under creative commons public domain
Show Usage
- degreeLicenseCertificate : Bundle/BundleExampleHdr and Practitioner/b06b2c2c-15dd-4e58-b27e-37326ba51407
ISO maintains the copyright on the country codes, and controls its use carefully. For further details see the ISO 3166 web page: https://www.iso.org/iso-3166-country-codes.html
Show Usage
- ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code : EHDSICountry and PatientHdrMyHealthEu
Produced by HL7 under the terms of HL7® Governance and Operations Manual relating to Intellectual Property (Section 16), specifically its copyright, trademark and patent provisions. This document is licensed under Creative Commons "No Rights Reserved" (CC0).
Show Usage
- Absent and Unknown Data - IPS : EHDSIAbsentOrUnknownDevice , EHDSIAbsentOrUnknownProblem and EHDSIAbsentOrUnknownProcedure
The UCUM codes, UCUM table (regardless of format), and UCUM Specification are copyright 1999-2009, Regenstrief Institute, Inc. and the Unified Codes for Units of Measures (UCUM) Organization. All rights reserved. https://ucum.org/trac/wiki/TermsOfUse
Show Usage
- Unified Code for Units of Measure (UCUM) : Bundle/BundleExampleHdr , EHDSIUnit ... Show 6 more
This artifact includes content from International Standard Classification of Occupations (ISCO). ISCO is copyright International Labour Organization (ILO). Terms & Conditions in http://www.ilo.org/global/copyright/lang--en/index.htm
Show Usage
- International Standard Classification of Occupations (ISCO) : Bundle/BundleExampleHdr , EHDSIHealthcareProfessionalRole , PractitionerRole/b975ec26-4ecf-4588-9fa2-afbb0d9fc530 and PractitionerRoleHdrMyHealthEu
This material contains content from LOINC . LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license . LOINC® is a registered United States trademark of Regenstrief Institute, Inc.
Show Usage
- LOINC : Bundle/BundleExampleHdr , Composition/ExampleCompositionHdr ... Show 9 more
This material contains content that is copyright of SNOMED International. Implementers of these specifications must have the appropriate SNOMED CT Affiliate license - for more information contact https://www.snomed.org/get-snomed or info@snomed.org .
Show Usage
- SNOMED Clinical Terms® (SNOMED CT®) : AllergyIntolerance/5b87ea1e-01ad-4239-81ec-3a16b5c4f4ec , BodyStructure/BodyStructureHdrExample ... Show 28 more
This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html
Show Usage
Unless otherwise indicated, reproduction of material posted on Council of Europe websites, and reproduction of photographs for which the Council of Europe holds copyright – see legal notice \“photo credits\” – is authorised for private use and for informational and educational uses relating to the Council of Europe’s work. This authorisation is subject to the condition that the source be indicated and no charge made for reproduction. Persons wishing to make some other use than those specified above, including commercial use, of information and text posted on these sites are asked to apply for prior written authorisation to the Council of Europe, Directorate of Communication.
Show Usage
- EDQM Standard Terms : DosageHdrMyHealthEu , EHDSIDoseForm ... Show 7 more
Used by permission of HL7 Europe, all rights reserved Creative Commons License
Show Usage
- Temporary HDR Code System : CompositionHdrMyHealthEu

hl7.fhir.us.hai: Healthcare Associated Infection Implementation Guide ®© HL7 | CC0 ( src )

((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol ( src )

((R)-7-((1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl)amino)-2-(6-methoxypyridin-2-yl)pyrazolo [1,5-a]pyrimidine-6-carboxamide) ( src )

((Trans)-4-((2-(((2-chloro-4-((((R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)carbamoyl)oxy)ethyl)(methyl)amino)cyclohexyl 2-hydroxy-2,2-di(thiophen-2-yl)acetate ( src )

(-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluorobutyl-1-sulfonate ( src )

(R)-(-)-N-(2-(3-((6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)carbonyl)piperidino)ethyl)-4-fluorobenzamide ( src )

(R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl) pyrrolidin-1-yl)(5-fluoropyridin-2-yl)methanone ( src )

(R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl)pyrrolidin-1-yl)(5-hydroxy-6-methylpyridin-2-yl)methanone ( src )

(R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile ( src )

(R)-1-(1-Acryloylpiperidin-3-yl)-4-amino-N-(4-(2-(dimethylamino)-2-oxoethyl)-2,3-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide ( src )

(R)-1-(5-tert-butyl-indan-1-yl)-3-(1H-indazol-4-yl)-urea ( src )

(R)-1-(tert-butyl)-N-(8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide ( src )

(R)-2-(4-(Cyclopropylsulfonyl)phenyl)-N-(pyrazin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide ( src )

(R)-2-(5-cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-(1,2,4)triazolo(4,3-a)pyrimidin-5-yl)phenyl)-n,n,n-trimethylethanaminium methanesulfonate ( src )

(R)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-[11C]methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one ( src )

(R)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dihydro-6H-pyrido(4,3-d)pyrimidin-5-one ( src )

(R)-3,3,3-trifluoro-N-(2-fluoro-5-trifluoromethylbenzyl)-2-hydroxy-2-phenylpropanamide ( src )

(R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea ( src )

(R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea fumarate ( src )

(R)-3-(1-Cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)ureido)piperidine-1-carboxamide ( src )

(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione ( src )

(R)-3-Chloro-1,2-propanediol ( src )

(R)-4-((3-(1H-Imidazol-1-yl)-6,6-dimethylcyclohex-2-en-1-yl)(methyl)amino)-2-(trifluoromethyl)benzonitrile ( src )

(R)-4-((5-(3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one ( src )

(R)-4-((5-(3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one mesilate ( src )

(R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol ( src )

(R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile ( src )

(R)-6-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-N-(1-phenylethyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine ( src )

(R)-ALPHA-GLYCEROPHOSPHORYLETHANOLAMINE MONOHYDRATE ( src )

(R)-Bicalutamide ( src )

(R)-Deuteropioglitazone ( src )

(R)-Deuteropioglitazone hydrochloride ( src )

(R)-Glycidyl tosilate ( src )

(R)-Ketamine ( src )

(R)-Ketamine hydrochloride ( src )

(R)-Mequitazine ( src )

(R)-N-(1-(3-(Cyclopentyloxy)phenyl)ethyl)-3-((2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methoxy)propane-1-sulfonamide ( src )

(R)-N-(1-carboxy-3-((phenylacetyl)amino)propyl)-L-leucyl-N,O-dimethyl-L-tyrosinamide ( src )

(R)-N-(3-(2-Chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide ( src )

(R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide ( src )

(R)-Otenaproxesul ( src )

(R)-Styrene oxide ( src )

(R)-Warfarin ( src )

(R)-alpha-glycerophosphorylethanolamine ( src )

(R)-fadrozole phosphate ( src )

(R)-troloxamide quinone ( src )

(S)-4-(((R)-6-(2-Chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic acid ( src )

(r)-4-((4-(((4-(tetrahydrofuran-3-yloxy)-1,2-benzisoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol ( src )

1-(4'-(3-methyl-4-(((((R)-1-phenylethyl)oxy)carbonyl)amino)isoxazol-5-yl)biphenyl-4-yl)cyclopropanecarboxylic acid ( src )

2-((R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl)-N-((R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)acetamide ( src )

3-((S)-4-(5-((4-(4-chlorothiophen-2-yl)-5-(((R)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)carbamoyl)pyrazin-2-yl)-2-methylpiperazin-1-yl)propanoic acid ( src )

4-[(5-bromo-4-{[(R)-1-hydroxypropan-2-yl]amino}pyrimidin-2-yl)amino]benzenesulfonamide ( src )

4-[4-[(R)-[2-(4-Chlorophenyl)phenyl]-hydroxymethyl]piperidin-1-yl]-N-[4-[[(2R)-4-[2-hydroxyethyl(methyl)amino]-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide ( src )

4-{(R)-(3-aminophenyl)[4-(4-fluorobenzyl)-piperazin-1-yl]methyl}-N,N-diethylbenzamide ( src )

4-{(R)-(3-aminophenyl)[4-(4-fluorobenzyl)-piperazin-1-yl]methyl}-N,N-diethylbenzamide sesquifumarate ( src )

5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one ( src )

9-[2-(R)-(Phosphonomethoxy)propyl]-2,6-diaminopurine ( src )

ADENOSINE, (P(R))-5'-O-((R)-HYDROXYMERCAPTOPHOSPHINYL)-P-THIOADENYLYL-(2'->5')-, CYCLIC NUCLEOTIDE ( src )

ADENOSINE, (P(R))-5'-O-((R)-HYDROXYMERCAPTOPHOSPHINYL)-P-THIOADENYLYL-(2'->5')-, CYCLIC NUCLEOTIDE, SODIUM SALT (1:2) ( src )

AMPHISOL® K ( src )

Archetype ID openEHR-EHR-CLUSTER.anatomical_location.v1 Concept name Anatomical Location Concept description Record details about an anatomical location. Keywords location, site, anatomical Copyright © openEHR Foundation Purpose To record details about anatomical location. Misuse Not for specifiying unilateral/bilateral occurrence - this is related to an evaluation which perhaps includes multiple locations. Author Author name: Heather Leslie Organization: Ocean Informatics Email: heather.leslie@oceaninformatics.com Date of Origination: 2008-11-10 Translator Norwegian Bokmål: Lars Bitsch-Larsen, Haukeland University Hospital of Bergen, Norway, MD, DEAA, MBA, spec in anesthesia, spec in tropical medicine. Arabic (Syria): Mona Saleh Other contributors Heather Leslie, Ocean Informatics, Australia (Editor) Ian McNicoll, freshEHR Clinical Informatics, United Kingdom (Editor) Dunmail Hodkinson, Black Pear Software Ltd, UK References Use cases: - 5LICS, midclavicular line - L forearm, 2cm anterior to the cubital fossa - Right iliac fossa - 5 cm below L tibial tuberosity - 2 cm medial to R nipple - 4 cm below R costal margin in midclavicular line - R femur - midline nose - medial aspect of R great toe nail. ( src )

Code of Federal Regulation 21CFR§1271.290(c) ( src )

Copyright/Legal: The Value Set incorporates SNOMED CT®, used by permission of the International Health Terminology Standards Development Organisation, trading as SNOMED International. SNOMED CT was originally created by the College of American Pathologists. SNOMED CT is a registered trademark of the International Health Terminology Standards Development Organisation, all rights reserved. For further information on the use of SNOMED CT, including translations, implementers of MyHealth@EU should review usage terms or directly contact SNOMED International: info@snomed.org. ( src )

Copyright/Legal: This material contains content from LOINC (http://loinc.org). LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license at http://loinc.org/license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc ( src )

Methyl (R)-3-chloro-3'-fluoro-4'-(1-(1-(2,2,2-trifluoroacetamido)cyclopropane-1-carboxamido)ethyl)-[1,1'-biphenyl]-2-carboxylate ( src )

Methyl(R)-4-((3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-2-ylmethyl)amino)butyl)amino)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate ( src )

Methyl(R)-4-((3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-3-ylmethyl)amino)butyl)amino)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate ( src )

MyHealth@Eu Hospital Discharge Report - Local Development build (v0.1.0-preview) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions ( src )

N-(2-hydroxyethyl)-2-((Z)-4,4,7-trifluoro-1-(4-((R)-2-fluoropropoxy)-2-(trifluoromethyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-ylidene)acetamide ( src )

N-Tert-butyl-3-[(R)-(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide ( src )

Produced by HL7 under the terms of HL7® Governance and Operations Manual relating to Intellectual Property (Section 16), specifically its copyright, trademark and patent provisions. This document is licensed under Creative Commons "No Rights Reserved" (CC0). Show Usage * Absent and Unknown Data - IPS: EHDSIAbsentOrUnknownDevice, EHDSIAbsentOrUnknownProblem and EHDSIAbsentOrUnknownProcedure ( src )

Sodium (R)-2-(2-amino-3-(1H-indol-3- yl)propanamido)-2-methylpropanoate-propan-2-ol ( src )

TEKPRINT ® SB 1010 N RED2 ( src )

The Value Set is used for coding clinical manifestation of the allergic reaction. It is defined as the union of: (a) eHDSIIllnessandDisorder (b) eHDSIReactionAllergy (c) eHDSIExceptionalValue ( src )

The Value Set is used for coding reason or reasons for admission, e.g. problem, procedure or finding. It is defined as the union of: (a) eHDSIIllnessesAndDisorder (b) eHDSIRareDisease (c) eHDSIProcedure (d) eHDSIExceptionalValue ( src )

The Value Set is used for coding reason or reasons for medication. It is defined as the union of: (a) eHDSIIllnessandDisorder (b) eHDSIReactionAllergy (c) eHDSIRareDisease (c) eHDSIExceptionalValue ( src )

The Value Set is used for coding s specific allergen or other agent/substance (drug, food, chemical agent, etc.) to which the patient has an adverse reaction propensity. It is defined as the union of: (a) eHDSIAllergenNoDrug (b) eHDSISubstance (c) eHDSIActiveIngredient (d) eHDSIAbsentOrUnknownAllergy (e) eHDSIExceptionalValue ( src )

The Value Set is used for coding the patient's relevant problems or diagnoses. It is defined as the union of: (a) eHDSIIllnessandDisorder (b) eHDSIRareDisease (c) eHDSIOncologyDisease (d) eHDSIAbsentOrUnknownProblem (e) eHDSIExceptionalValue ( src )

The Value Set is used to code the value of imaging observation result. It is defined as the union of: (a) eHDSIImagingFinding (b) eHDSIPresenceAbsence (c) eHDSIExceptionalValue ( src )

The Value set is used for the standard vital sign and anthropometric observation codes. It is defined as the union of: (a) eHDSIVitalSignCode (b) eHDSIAnthropometricCode (c) eHDSIExceptionalValue ( src )

There are examples where a medication request may include the option of an oral dose or an Intravenous or Intramuscular dose. For example, "Ondansetron 8mg orally or IV twice a day as needed for nausea" or "Compazine® (prochlorperazine) 5-10mg PO or 25mg PR bid prn nausea or vomiting". In these cases, two medication requests would be created that could be grouped together. The decision on which dose and route of administration to use is based on the patient's condition at the time the dose is needed. ( src )

This material contains content from LOINC. LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc. Show Usage * LOINC: Bundle/BundleExampleHdr, Composition/ExampleCompositionHdr... Show 9 more , CompositionHdrMyHealthEu, EHDSIHospitalDischargeReportType, EHDSIImagingCode, EHDSIVitalSignCode, Observation/9c72df9a-c459-45ea-bedf-b89568a8378a, Observation/ExampleObservationImgFindingHdr, Observation/ObservationVitalSignsExampleMyHealthEu, Observation/d532c253-9bd1-433a-a08e-fb6384f4a6b6 and ObservationImgFindingHdrMyHealthEu ( src )

This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html Show Usage * AllergyIntolerance Clinical Status Codes: AllergyIntolerance/5b87ea1e-01ad-4239-81ec-3a16b5c4f4ec and Bundle/BundleExampleHdr * AllergyIntolerance Verification Status: AllergyIntolerance/5b87ea1e-01ad-4239-81ec-3a16b5c4f4ec and Bundle/BundleExampleHdr * Condition Category Codes: Condition/ExampleConditionHdr * Condition Clinical Status Codes: Condition/ExampleConditionHdr * ConditionVerificationStatus: Condition/ExampleConditionHdr * DataAbsentReason: EHDSIDataAbsentReason * Discharge disposition: EHDSIDischargeDisposition * Flag Category: Flag/ExampleFlagHdr * Location type: University Hospital Radiology Dept. * Observation Category Codes: Bundle/BundleExampleHdr, EHDSIObservationCategory... Show 5 more , Observation/9c72df9a-c459-45ea-bedf-b89568a8378a, Observation/ExampleObservationImgFindingHdr, Observation/ObservationVitalSignsExampleMyHealthEu, Observation/d532c253-9bd1-433a-a08e-fb6384f4a6b6 and ObservationImgFindingHdrMyHealthEu * Organization type: Bundle/BundleExampleHdr and University Hospital Berlin * Observation Reference Range Meaning Codes: Bundle/BundleExampleHdr, EHDSIReferenceRangeMeaning and Observation/9c72df9a-c459-45ea-bedf-b89568a8378a * Sex Parameter For Clinical Use: EHDSIReferenceRangeAppliesTo * identifierType: ObservationImgFindingHdrMyHealthEu * ActCode: Bundle/BundleExampleHdr, EHDSIEncounterClass, Encounter/b49cdbed-299c-4b95-aa9d-273811521147 and EncounterHdrMyHealthEu * ActPriority: EHDSIAdmissionUrgency and EncounterHdrMyHealthEu * NullFlavor: EHDSIExceptionalValue, MedicationDispense/DISP-001, MedicationRequest/ExampleMedicationRequestHdr and MedicationStatement/MS-001 * ObservationInterpretation: Bundle/BundleExampleHdr, EHDSIObservationInterpretation and Observation/9c72df9a-c459-45ea-bedf-b89568a8378a * ParticipationType: EHDSIPerformerFunction and EncounterHdrMyHealthEu * RoleClass: EHDSIRoleClass and PatientHdrMyHealthEu * RoleCode: EHDSIClinLocRoleType, EHDSIPersonalRelationship and PatientHdrMyHealthEu * TimingEvent: EHDSITimingEvent, MedicationDispense/DISP-001 and MedicationRequest/ExampleMedicationRequestHdr ( src )

External References

Internal Images